Elafibranor - Moligand™, 10mM in DMSO , Agonist of Peroxisome proliferator-activated receptor-α;Agonist of Peroxisome proliferator-activated receptor-γ, CAS No.923978-27-2, Agonist of Peroxisome proliferator-activated receptor-α;Agonist of Peroxisome proliferator-activated receptor-γ

CAS: 923978-27-2 Cat. No.: E408744 Molecular Weight: 384.49 EC Number: 815-538-9

GRADE & PURITY Moligand™, 10mM in DMSO

Synonyms

GFT505 | Propanoic acid, 2-​[2,​6-​dimethyl-​4-​[(1E)​-​3-​[4-​(methylthio)​phenyl]​-​3-​oxo-​1-​propen-​1-​yl]​phenoxy]​-​2-​methyl-

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

Overview

Information

Elafibranor (GFT505) is an agonist of theperoxisome proliferator-activated receptor-α(PPAR-alpha)andperoxisome proliferator-activated receptor-δ(PPAR-δ). It improves insulin sensitivity, glucose homeostasis, and lipid metabolism and reduces inflammation.
In vitro

GFT505 is a novel PPAR modulator that shows a preferential activity on PPAR-α and concomitant activity on PPAR-δ.

In vivo

Elafibranor (GFT505) is a dual PPARα/δ agonist that has demonstrated efficacy in disease models of nonalcoholic fatty liver disease (NAFLD)/NASH and liver fibrosis. In the rat, GFT505 concentrated in the liver with limited extrahepatic exposure and underwent extensive enterohepatic cycling. Elafibranor confers liver protection by acting on several pathways involved in NASH pathogenesis, reducing steatosis, inflammation, and fibrosis. GFT505 improved liver dysfunction markers, decreased hepatic lipid accumulation, and inhibited proinflammatory (interleukin-1 beta, tumor necrosis factor alpha, and F4/80) and profibrotic (transforming growth factor beta, tissue inhibitor of metalloproteinase 2, collagen type I, alpha 1, and collagen type I, alpha 2) gene expression.
Cell Data

cell lines：

Concentrations：

Incubation Time：

Powder Purity:≥98%

Specifications

Synonyms

GFT505 | Propanoic acid, 2-​[2, ​6-​dimethyl-​4-​[(1E)​-​3-​[4-​(methylthio)​phenyl]​-​3-​oxo-​1-​propen-​1-​yl]​phenoxy]​-​2-​methyl-

Specifications & Purity

Moligand™, 10mM in DMSO

Biochemical and Physiological Mechanisms

Elafibranor (GFT505) is an agonist of the peroxisome proliferator-activated receptor-α(PPAR-alpha) and peroxisome proliferator-activated receptor-δ(PPAR-δ). It improves insulin sensitivity, glucose homeostasis, and lipid metabolism and reduces inflammatio

Storage

Store at -80°C

Shipped In

Dry ice packs + Cold packs

This product requires cold chain shipping. Ground and other economy services are not available.

Grade

Moligand™

Action Type

AGONIST

Mechanism of action

Agonist of Peroxisome proliferator-activated receptor-α;Agonist of Peroxisome proliferator-activated receptor-γ

Product Properties

• ALogP: 5.477
• hba_count: 3
• Rotatable Bond: 7

Names and Identifiers

• Isomeric SMILES: CC1=CC(=CC(=C1OC(C)(C)C(=O)O)C)/C=C/C(=O)C2=CC=C(C=C2)SC
• Molecular Weight: 384.49
• Reaxy-Rn: 24554260
• Reaxys-RN_link_address: https://www.reaxys.com/reaxys/secured/hopinto.do?context=S&query=IDE.XRN=24554260&ln=

Associated Targets(Human)

PPARA Tclin Peroxisome proliferator-activated receptor alpha (0 Activities)

Discover Target: PPARA

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

PPARD Tchem Peroxisome proliferator-activated receptor delta (0 Activities)

Discover Target: PPARD

Activity Type	Activity Value -log(M)	Mechanism of Action	Activity Reference	Publications (PubMed IDs)

Chemical and Physical Properties

• Solubility: Solubility (25°C) In vitro DMSO: 29 mg/mL (195.68 mM)
• DMSO(mg / mL) Max Solubility: 76
• DMSO(mM) Max Solubility: 197.6644386
• Water(mg / mL) Max Solubility: ＜1